Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2006 1
2012 4
2013 1
2014 3
2015 7
2016 20
2017 81
2018 122
2019 131
2020 160
2021 251
2022 341
2023 530
2024 1052
2025 1706
2026 1110

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,954 results

Results by year

Filters applied: . Clear all
Page 1
Safety of Semaglutide.
Smits MM, Van Raalte DH. Smits MM, et al. Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34305810 Free PMC article. Review.
Furthermore, we discuss whether effects are specific for semaglutide or a class effect. We conclude that semaglutide induces mostly mild-to-moderate and transient gastrointestinal disturbances and increases the risk of biliary disease (cholelithiasis). ...Due to its …
Furthermore, we discuss whether effects are specific for semaglutide or a class effect. We conclude that semaglutide induces m …
Semaglutide for the treatment of obesity.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Chao AM, et al. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. Trends Cardiovasc Med. 2023. PMID: 34942372 Free PMC article. Review.
Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management. This paper reviews data on the mechanism of action, weight-loss and cardiometabolic efficacy, and safety of semaglu …
Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chron …
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Davies M, et al. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. Lancet. 2021. PMID: 33667417 Clinical Trial.
FINDINGS: From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2.4 mg (n=404), semaglutide 1.0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis. ...Gastrointestinal adverse events, …
FINDINGS: From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2.4 mg (n=404) …
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM. Tan HC, et al. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23. J ASEAN Fed Endocr Soc. 2022. PMID: 36578889 Free PMC article.
Risk for discontinuation due to adverse events was twice as likely in the semaglutide group (RR 2.19, 95%CI [1.36,3.55], p=0.001) and the risk for serious adverse events was 1.6 times more likely for semaglutide (RR1.60, 95%CI [1.24, 2.07], p=0.0003). ...This suppor …
Risk for discontinuation due to adverse events was twice as likely in the semaglutide group (RR 2.19, 95%CI [1.36,3.55], p=0.001) and …
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nøhr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilvásy-Szabó A, Willenbrock H, Secher A, Knudsen LB, Hogendorf WFJ. Gabery S, et al. JCI Insight. 2020 Mar 26;5(6):e133429. doi: 10.1172/jci.insight.133429. JCI Insight. 2020. PMID: 32213703 Free PMC article.
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers glucose levels, and reduces cardiovascular risk in patients with diabetes. ...Semaglutide induced central c-Fos activation in 10 brain areas, including hindbrain areas directly target …
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers glucose levels, and reduces cardiovascular risk in …
Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G, Krauthamer M, Bjalme-Evans M. Singh G, et al. J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27. J Investig Med. 2022. PMID: 34706925 Free PMC article. Review.
The SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolog), respectively, on participants with type 2 diabetes. The STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglut …
The SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolo …
Clinical Pharmacokinetics of Semaglutide: A Systematic Review.
Yang XD, Yang YY. Yang XD, et al. Drug Des Devel Ther. 2024 Jun 25;18:2555-2570. doi: 10.2147/DDDT.S470826. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38952487 Free PMC article.
The AUC and C(max) of both oral and subcutaneous semaglutide increased with dose. Food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure. ...The existing pharmacokinetic data can assist in developing a …
The AUC and C(max) of both oral and subcutaneous semaglutide increased with dose. Food and various dosing conditions including water …
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. Bikou A, et al. Expert Opin Pharmacother. 2024 Apr;25(5):611-619. doi: 10.1080/14656566.2024.2343092. Epub 2024 Apr 18. Expert Opin Pharmacother. 2024. PMID: 38629387
INTRODUCTION: Semaglutide, a glucagon-like peptide-1 receptor agonist, is associated with significant weight loss, yet its impact on lean body mass remains insufficiently understood. This review investigates the effect of semaglutide on lean mass in the context of o …
INTRODUCTION: Semaglutide, a glucagon-like peptide-1 receptor agonist, is associated with significant weight loss, yet its impact on …
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, Vasilakou D, Kakaletsis N, Tsapas A, Bekiari E. Karagiannis T, et al. Diabetologia. 2024 Jul;67(7):1206-1222. doi: 10.1007/s00125-024-06144-1. Epub 2024 Apr 13. Diabetologia. 2024. PMID: 38613667 Free PMC article.
In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions rangin …
In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg …
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, Cestari D, Mallery R, Abbasi B, Bouffard M, Chwalisz BK, Estrela T, Rizzo JF 3rd. Hathaway JT, et al. JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296. JAMA Ophthalmol. 2024. PMID: 38958939 Free PMC article.
In the population with T2D, 17 NAION events occurred in patients prescribed semaglutide vs 6 in the non-GLP-1 RA antidiabetes cohort. The cumulative incidence of NAION for the semaglutide and non-GLP-1 RA cohorts over 36 months was 8.9% (95% CI, 4.5%-13.1%) and 1.8% …
In the population with T2D, 17 NAION events occurred in patients prescribed semaglutide vs 6 in the non-GLP-1 RA antidiabetes cohort. …
4,954 results